Analysts have a price target between $2 and $3.
Earnings report on 17 Feb 2021.
They launch their first FDA-approved product Vyleesi to market in Q3 of 2020 which could potentially help 6 million women suffering from HSDD in the USA alone. This product generated $800 million in sales in Q3 and will grow over time as Palatin is currently the only company offering...
